WilmerHale Guides Corvia Medical in $35M Strategic Investment by Edwards Lifesciences

• 3.11.2019

Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, has entered into an agreement with Edwards Lifesciences. The agreement includes a $35 million investment and provides the exclusive option for Edwards to acquire the company at a later date. Funds will be used to complete the REDUCE LAP-HF II clinical trial of the InterAtrial Shunt Device (IASD®), the world's first transcatheter device for the treatment of heart failure with preserved (HFpEF) and mid-range ejection fraction (HFmrEF).

The WilmerHale team representing Corvia in this transaction was led by Jason Kropp and includes Bill Caporizzo, Belinda Juran, Scott Kilgore, Hal Leibowitz, Bruce Manheim, George Shuster, Kimberly Wethly, Andrew Langworthy, Alex Civetta, Byron Crowe, Todd Rosenthal and Ben Kelsey.